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Abstract
Background: Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with
clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical
activity of subsequent treatment with targeted therapies in patients progressing on axitinib is of interest.
Methods: Patients with advanced renal cell carcinoma of any pathologic subtype treated with at least one cycle
(four weeks) of axitinib followed by at least one subsequent targeted therapy were investigated in a retrospective
analysis. Patient characteristics, duration of treatment and clinical outcomes were analyzed for axitinib and each
subsequent line of therapy by Response Evaluation Criteria in Solid Tumors (RECIST).
Results: Twenty-five mRCC patients who received at least one approved targeted agent following axitinib were
identified. Eight percent of patients achieved a partial response (one patient each to sunitinib and pazopanib) and
42 % had a best response of stable disease to the first therapy after axitinib. The estimated median duration of
therapy was 4.4 months (range, 0.2–27.5+). Twelve patients received a second post-axitinib targeted therapy. Six out
of 11 evaluable patients (55 %) had a best response of SD. The estimated median duration of treatment was 4.8
months (range, 0.7–19.1+).
Conclusion: Objective responses and stable disease is observed to post-axitinib targeted therapies and prospective
studies are needed for validating role of predictive biomarkers.
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Background
Renal cell carcinoma (RCC) is a biologically heteroge-
neous disease with distinct genetic and metabolic defects
[1]. Over the past decade, recognition that von Hippel-
Lindau (VHL) gene mutations cause overexpression of
vascular endothelial growth factor (VEGF) and increased
tumor angiogenesis has led to development of multiple
agents targeting this protein and its receptor.
Currently approved therapies for treatment of patients
with mRCC include bevacizumab (plus interferon alfa), a
humanized monoclonal antibody that inhibits the VEGF
ligand, and the multi-targeted receptor tyrosine kinase
inhibitors, sunitinib, sorafenib, pazopanib and axitinib
(VEGFr- TKIs) [2–7]. Each agent has a slightly different
affinity for the VEGF and platelet derived growth factor
(PDGF) receptors, as well as for other receptor tyrosine
kinases [8]. Mammalian target of rapamycin (mTOR)
inhibitors, which include everolimus and temsirolimus
[9, 10] are also approved for treatment of mRCC, and do
not appear to have a direct effect on VEGF or its
receptors.
The most recently Food and Drug Administration (FDA)
approved agent for mRCC is axitinib, a second-generation,
indazole derived molecule that binds selectively to the
adenosine triphosphate (ATP)-binding intracellular domain
of VEGFR-1, 2, and 3 at sub-nanomolar concentrations.
The AXIS trial that led to the approval of axitinib was a
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phase 3, randomized controlled study comparing two
VEGFr TKIs, axitinib and sorafenib, in patients whose
disease progressed on initial systemic therapy [7].
Patients in each treatment arm had received first-line
treatment with sunitinib (54 %), cytokines (35 %),
bevacizumab (8 %), or temsirolimus (3 %). In the
overall population, patients treated with axitinib expe-
rienced a significantly longer median progression free
survival (PFS) than patients treated with sorafenib
(6.7 vs. 4.7 months; P < 0.0001). Secondary endpoints
included overall response rate (ORR), overall survival
(OS), and safety and tolerability. ORR was 19.4 % (95 % Cl
15.4–23.9 %) versus 9.4 % (95 % CI 6.6–12.9 %) for
axitinib and sorafenib, respectively. In the sub-group of
sunitinib-refractory patients, median PFS was 4.8 months
for patients treated with second-line axitinib and 3.4
months for patients treated with second-line sorafenib
(P = 0.0107). In the subgroup of cytokine-refractory pa-
tients, median PFS was 12.1 months for patients treated
with second-line axitinib and 6.5months for patients
treated with second-line sorafenib (P < 0.0001) [11]. The
longer median PFS values observed in cytokine-refractory
patients relative to sunitinib-refractory patients points to
partial cross-resistance with sequential VEGF-targeted
therapy [11]. This suggests that targeting of the same
pathway with sequential VEGFr-TKI therapy may follow a
law of diminishing returns due to unknown mechanisms
of increasing resistance [12].
Knowing that axitinib is the most biochemically potent of
the approved VEGFr inhibitors, and that there is possibility
of cross-resistance with sequential VEGF-targeting therapy,
the response to therapy after progressing on axitinib is of
clinical interest.
A retrospective review of patients from the Cleveland
Clinic Taussig Cancer Center (CCF) and MD Anderson
Cancer Center (MDACC) was thus undertaken to
characterize and evaluate the response to subsequent
systemic therapy in patients who had progressed on
axitinib.
Methods
Study design and patient characteristics
Patients from CCF or MDACC were identified through
prospectively maintained databases and included in the
study, which was approved by Cleveland Clinic and UT
MD Anderson institutional review board. The initial
criteria for case identification included a diagnosis of
metastatic RCC of any pathologic subtype and treatment
with at least one cycle (four weeks) of axitinib. Eighty-
one patients treated with axitinib between November
2003 and August 2010 were initially identified; 25
patients (17 (68 %) from CCF and 8 (32 %) from
MDACC) received at least one approved targeted agent
following axitinib and were included in this analysis. The
remaining patients were excluded due to ≤ 4 weeks on
axitinib (n = 3), ongoing axitinib therapy (n = 16), lack of
subsequent systemic therapy (n = 13), lost to follow up
(n = 11), receiving non targeted or investigational agents
post-axitinib (n = 11) or were not evaluable (n = 2). All
patients were enrolled in axitinib clinical trials given that
axitinib therapy pre-dated FDA approval.
Data collection was performed via retrospective review
of each patient’s medical record and recorded on a
spreadsheet standardized between the two centers. Pa-
tient characteristics, duration of treatment and clinical
outcomes were analyzed for axitinib and each subse-
quent line of therapy. Objective response was defined
according to RECIST version 1.0. All imaging studies
were done at MDACC or CCF and response was evalu-
ated by treating physicians at each institute. There was
no centralized review of the radiological findings.
Response beyond the second subsequent therapy was
not evaluated because of lack of sufficient data.
Statistical analyses
Categorical data were summarized as frequency counts
and percentages and measured data by medians and
ranges. The Kaplan Meier method was used to summarize
the duration of subsequent treatments since some patients
were still receiving therapy at the time of analysis. The
Wilcoxon signed rank test was used to compare treatment
duration with axitinib to the duration on subsequent
therapy in patients with complete data. Data analysis was
conducted using SAS version 9.2 (SAS Inc., Cary NC)
Results
Patient characteristics
Twenty-five patients (17 (68 %) from CCF and 8 (32 %)
from MDACC) received at least one approved targeted
agent following axitinib and were included in this analysis.
Patient characteristics at the start of axitinib were typical
of an advanced RCC population and included 72 % male,
median age 59 (range, 44–78); 96 % clear cell; 92 % prior
nephrectomy; 72 % previously-treated. Patients had favor-
able (30 %) or intermediate (65 %) risk disease based on
Heng criteria [13]. The overall RECIST-defined objective
response rate to axitinib was 56 % (one complete and 13
partial response) and the median duration of treatment
with axitinib was 11.2 months (range, 1.1–90) (Table 1).
Response to first subsequent therapy post axitinib
Following axitinib therapy, patients were treated with VEGF
receptor inhibitors (n = 18) or mTOR inhibitors (n = 7).
Overall, 8 % of patients achieved a partial response (one pa-
tient each to sunitinib and pazopanib) and 42 % had a best
response of stable disease (nine patients to VEGF receptor
inhibitors and four patients to mTOR inhibitors). The
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estimated median duration of subsequent therapy was 4.4
months (range, 0.2–27.5+) (Table 2).
The response to first subsequent therapy was evalu-
ated in the subgroup of patients who had received axi-
tinib as second-line or later therapy (72 %, 18/25) and in
patients who had received no therapy prior to axitinib
(28 %, 7/25). Ten patients (55 %) had a best response of
stable disease in the group of patients who had received
axitinib as second-line or later therapy as compared to
three (42 %) in the latter group. One patient achieved
partial response in both groups (Table 3).
Response to second subsequent therapy post axitinib
Eleven of twelve patients who received a second post-
axitinib targeted therapy were treated with VEGF recep-
tor inhibitors (n = 3) or mTOR inhibitors (n = 8). No
partial responses were observed. However, six of 11 eva-
luable patients (55 %) had a best response of SD to
mTOR inhibitors. The estimated median duration of
treatment was 4.8 months (range, 0.7–19.1+).
Patient response to subsequent therapy was generally
less favorable than the response to axitinib. This was
true also for four patients who discontinued axitinib due
to toxicity and not due to progressive disease. Among 13
evaluable patients who achieved a CR or PR on axitinib,
only 2 (15 %) achieved a PR on their next systemic
therapy, 7 (54 %) had a best response of stable disease,
and 4 (31 %) progressed.
Further, Fig. 1 delineates two populations The majority
of the 14 patients who had a prolonged response to axi-
tinib had brief responses (<3 months) to subsequent
therapies; however seven patients (28 %) remained on
their first post-axitinib therapy longer than on axitinib.
Despite this, the overall duration of axitinib treatment
was longer as compared to subsequent therapy (median
11.2 versus 4.4 months, p = 0.04). All of these seven
patients had clear cell RCC without sarcomatoid features
and six of these seven patients received sunitinib or
pazopanib as first subsequent therapy and only one
received temsirolimus.
Table 1 Patient characteristics and clinical outcomes to axitinib
Characteristic N (%)
Gender
Male 18 (72 %)
Female 7 (28 %)
Age at Start of Axitinib (years)a
Median (range) 59 (44-78)
Histology
Clear cell 24 (96 %)
Unclassified 1 (4 %)
Prior Nephrectomy
No 2 (8 %)
Yes 23 (92 %)
Prior Systemic Treatment
No 7 (28 %)
Yes 18 (72 %)
IFN and/or IL-2 11 (44 %)
Sorafenib 9 (36 %)
Sunitinib 6 (24 %)
Temsirolimus 1 (4 %)
Bevacizumab 1 (3 %)
Otherb 4 (16 %)
Interval from Dx of Mets to Axitiniba
Median in months (range) 20.1 (0.2–49.9)
ECOG PS
0 7 (28 %)
1 18 (72 %)
Heng Risk Groupc
Favorable 7 (30 %)
Intermediate 15 (65 %)
Unfavorable 1 (4 %)
Sites of Metastatic Disease
Lung 20 (80 %)
Lymph nodes 13 (52 %)
Bone 6 (24 %)
Liver 5 (20 %)
Adrenal 5 (20 %)
Pancreas 4 (16 %)
Brain 2 (8 %)
Otherd 12 (48 %)
Best Response to axitinib
CR 1 (4 %)
PR 13 (52 %)
SD 10 (40 %)
PD 1 (4 %)
Table 1 Patient characteristics and clinical outcomes to axitinib
(Continued)
Reason Axitinib Stopped
PD 21 (84 %)
Toxicity 4 (16 %)
Duration of Treatment
Median in months (range) 11.2 (1.1–90.0)
amissing for one patient
balone or in combination: thalidomide (n = 3); gemcitabine,5-FU, ABX-EGF,
capecitabine, lenalidomide, suramin, vinblastine (n = 1 each)
cmissing for two patients
dkidney/renal bed (n = 5); pleura (n = 4); abdominal wall, muscle, omentum,
pelvic mass, retroperitoneum, soft tissue (n = 1 each)
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Discussion
The standard of care in metastatic RCC is the empiric
and sequential use of systemic therapies, most of which
target VEGF. Previous retrospective and prospective evi-
dence points to lack of complete cross-resistance to
sequential VEGF-targeting therapies [14, 15], although
in general the clinical activity decreases with drugs given
later in the sequence. The reasons for development of
resistance to initial therapy and factors affecting re-
sponse to subsequent therapy are not well understood at
present. The present analysis demonstrates that clinical
responses (objective partial responses and stable disease)
are possible if VEGF receptor inhibitors are given after
axitinib, although in general the activity of subsequent
therapy is less than that observed with axitinib.
It has been hypothesized that residual VEGF signaling
after VEGF-targeted therapy could account for the activ-
ity of VEGF-targeted agents in this setting. Given the in-
creased biochemical potency of axitinib, it was
hypothesized that therapy (specifically VEGF-targeted
therapy) after axitinib treatment may not result in clin-
ical benefit. Our retrospective data suggests that clinical
effect is seen in patients with metastatic RCC who re-
ceive systemic therapy after axitinib, not only as second
but also as third line. Two thirds of our patients had
received systemic therapy prior to axitinib and we
Table 2 Patient characteristics and clinical outcomes to post-axitinib systemic therapy




Interval from End of Axitinib Therapy to Start of Current Therapy
Median in weeks (range)
2.0 (0–41.7)a 37.4 (2.6–93.0)
Treatment N ( %) N ( %)
VEGF inhibitors 18 (72 %) 3 (25 %)
Sunitinib 8 (32 %) −0-
Pazopanib 6 (24 %) 1 (8 %)
Bevacizumab 4 (16 %) 2 (17 %)
mTOR inhibitors 7 (28 %) 8 (67 %)
Everolimus 5 (20 %) 5 (42 %)
Temsirolimus 2 (8 %) 3 (25 %)
Other −0- 1 (8 %)b
ECOG PS
0 3 (13 %) 2 (17 %)
1 19 (79 %) 9 (75 %)
2 2 (8 %)a 1 (8 %)
Heng Risk Group
Favorable 9 (41 %) 3 (30 %)
Intermediate 12 (55 %) 6 (60 %)
Unfavorable 1 (5 %)c 1 (10 %)d
Best Response
PD 2 (8 %) −0-
SD 13 (42 %) 6 (55 %)
PD 7 (28 %) 4 (36 %)
Not evaluable 3 (12 %) 1 (9 %)a
Reason Treatment Stopped
PD/Death 17 (68 %) 6 (54 %)
Toxicity 4 (16 %) 2 (18 %)
Treatment ongoing 4 (16 %) 3 (27 %)
Duration of Treatment (subsequent therapy)
Median in months (range)
4.4 (0.2–27.5+)a 4.8 (0.7–19.1+)a
amissing for one patient
bMK2206
cmissing for three patients
dmissing for two patients
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still observed objective responses on subsequent
therapies, median duration of therapy was over four
months and seven patients remained on first subse-
quent therapy longer than axitinib. This may be ex-
plained by the therapeutic effect of different target
engagement by the various VEGF multikinase inhibi-
tors [16, 17]. Our study also delineates two popula-
tions, one that responds better to axitinib and
another to subsequent therapy. This variable response
emphasizes possible role of molecular biomarkers in
guiding individualized patient management and im-
proving outcomes.
There are limitations to this analysis. This is a retro-
spective review of a small number of patients at two
specialized institutions with inability to overcome selec-
tion bias. Individual treating physicians at each institute
did the tumor assessment, thus limiting the reliability
and consistency of the percent changes in tumor burden
and the assessment of objective response.
Further prospective trials are evaluating second-line
treatment with approved or investigational agents in
patients with mRCC who were refractory to previous
treatment with a targeted agent. Other trials are evaluating
the optimal sequence of targeted agents in treatment-
Table 3 Prior treatments and clinical outcomes to axitinib and first subsequent therapy
Patient
ID
















1 IL-2 plus IFN 18 PR PD 28 Sunitinib PR
2 IL-2 plus IFN 90 PR PD 1 Bevacizumab SD
3 IL-2 plus IFN 24 SD PD 41 Sunitinib Not
evaluable
4 IL-2 6 PR PD 0 Pazopanib PD
5 IL-2 plus thalidomide, Sorafenib 41 PR PD 2 Sunitinib SD
6 IL-2/Bevacizumab 18 SD PD 3 Pazopanib SD
7 IL-2, sunitinib, IFN, sorafenib 8 SD PD 1 Bevacizumab PD
8 IL-2 plus IFN, BAY 43-9006, Sorafenib 31 PR Toxicity, RPLSa 10 Temserolimus SD
9 IFN,vinblastin plus thalidomide,IL-2,
Gemcitabine plus Capecitabine,
Sorafenib
53 PR Toxicity, MIb 7 Pazopanib SD
10 IFN, Sunitinib, Sorafinib 8 SD PD 35 Temserolimus SD
11 IFN, IL-2/thalidomide, IL-2/IFN, sunitinib,
sorafenib
11 SD PD 2 Bevacizumab PD
12 ABX-EGF, CC-5013, 5FU/suramin,
Sorafinib
4 SD PD 5 Sunitinib SD
13 Sunitinib 1 PD PD 0 Everolimus Not
evaluable
14 Sunitinb 3 SD PD 1 Everolimus PD
15 Sunitinib 3 SD PD 0 Everolimus SD
16 Sorafenib 19 PR PD 2 Sunitinib PD
17 Sorafenibb 41 PR PD 2 Sunitinib SD
18 Temsirolimus 6 PR Toxicity 0 Pazopanib SD
19 None 29 PR PD 3 Everolimus SD
20 None 20 PR PD 2 Everolimus PD
21 None 2 CR Toxicity 0 Pazopanib PR
22 None 4 SD PD 32 Sunitinib SD
23 None 13 PR PD 2 Bevacizumab PD
24 None 6 SD PD 2 Pazopanib SD
25 None 6 PR PD 3 Sunitinib Not
evaluable
aReversible Posterior Leukoencephalopathy Syndrome
bMyocardial Infarction
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naive patients with mRCC. Results of these trials may give
us some insight into efficacy of sequenced VEGFR – TKIs
and cross – resistance in metastatic renal cell carcinoma.
Conclusion
Objective responses and stable disease is observed with
post-axitinib targeted therapy, although efficacy is gener-
ally less than that seen with axitinib. Prospective studies
will help us understand if prior response or resistance to
axitinib predicts for clinical benefit to subsequent ther-
apy. Variable patient response to drugs in the same class
warrants prospective studies to validate role of predictive
biomarkers in guiding individualized therapies and im-
proving outcomes.




Availability of data and materials
The dataset supporting the conclusions of this article is
available at request from the corresponding author.
Abbreviations
MI: Myocardial Infarction; mRCC: metastatic renal cell carcinoma; ORR: overall
response rate; OS: overall survival; PDGF: platelet derived growth factor;
PFS: progression free survival; RCC: renal cell carcinoma; RECIST: response
evaluation criteria in solid tumors; RPLS: Reversible Posterior Leukoencephalopathy
Syndrome; VEGF: vascular endothelial growth factor; VHL: von Hippel-Lindau.
Competing interests
EJ has received research funding from and acted as consultants for Pfizer,
GlaxoSmithKline and Novartis. BR has received research funding from Pfizer
and acted as consultant for Pfizer. NT has received research funding from
and served on advisory board for Pfizer. LW has received honoraria from
Pfizer. RD has acted as a consultant for Novartis. JG has received research
funding from Pfizer, Novartis and Astellas and served on advisory board for
Pfizer, GSK, Astellas and Aveo. NC, HH and PE have no conflicts of interest.
Authors’ contributions
NC made substantial contribution to acquisition, analysis and interpretation
of data, drafting and submission of the manuscript. HH contributed to
design of the study, acquisition of the data and drafting of the manuscript.
PE contributed to the design of the study and performed the statistical
analysis. BR conceived the study, participated in its design and coordination
and contributed to interpretation of the data and drafting of the manuscript.
EJ, NT, LW, RD, JG participated in the design of the study, contributed to the
interpretation of the data and drafting of the manuscript. All authors read




This study was conducted without any specific source of funding.
Author details
1Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave., Cleveland, OH,
USA. 2University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
3University of Virginia, 1240 Lee St., Charlottesville, VA, USA. 4Veteran Affairs
Medical Center, 800 Irving Avenue, Syracuse, NY 13210, USA.
Received: 18 June 2015 Accepted: 15 March 2016
References
1. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a
metabolic disease. Nat Rev Urol. 2010;7(5):277–85.
2. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C,
Chevreau, M. Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J.O. Bay, I. Bodrogi, A.
Jagiello-Gruszfeld, and N. Moore. Bevacizumab plus interferon alfa-2a for
treatment of metastatic renal cell carcinoma: a randomised, double-blind
phase III trial. Lancet. 2007;370(9605):2103–11.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier, C.
Chevreau, E. Solska, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S.
Freeman, B. Schwartz, M. Shan, R. Simantov, and R.M. Bukowski. Sorafenib in
advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, S.
Oudard, S. Negrier, C. Szczylik, S.T. Kim, I. Chen, P.W. Bycott, C.M. Baum, and
R.A. Figlin. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med. 2007;356(2):115–24.
5. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, J.N. Atkins,
J. Picus, P. Czaykowski, J. Dutcher, and E.J. Small. Phase III trial of
bevacizumab plus interferon alfa versus interferon alfa monotherapy in
patients with metastatic renal cell carcinoma: final results of CALGB 90206. J
Clin Oncol. 2010;28(13):2137–43.
6. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, C.H. Barrios, P.
Salman, O.A. Gladkov, A. Kavina, J.J. Zarba, M. Chen, L. McCann, L. Pandite, D.F.
Roychowdhury, and R.E. Hawkins. Pazopanib in locally advanced or metastatic
renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;
28(6):1061–8.
7. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, M.D.
Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D.
Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S.
Kim, and R.J. Motzer. Comparative effectiveness of axitinib versus sorafenib
in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet.
2011;378(9807):1931–9.
Fig. 1 Treatment Duration with Axitinib vs First Subsequent (Post
– Axitinib) Systemic Therapy. Notes: Axitinib duration cropped at
30 months for two patients (actual durations were 53.1 and 90.0
months). Data points above the diagonal represent patients who
remained on treatment longer with subsequent therapy than
with axitinib; points below the diagonal represent the converse
Chittoria et al. BMC Cancer  (2016) 16:254 Page 6 of 7
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
Cell. 2011;144(5):646–74.
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, E.
Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy,
I.G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L.
Moore, and R.J. Motzer. Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, V.
Grunwald, J.A. Thompson, R.A. Figlin, N. Hollaender, A. Kay, and A. Ravaud.
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results
and analysis of prognostic factors. Cancer. 2010;116(18):4256–65.
11. Calvo E, Ravaud A, Bellmunt J. What is the optimal therapy for patients with
metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Cancer Treat Rev. 2013;39(4):366–74.
12. Bex A, Haanen J. Tilting the AXIS towards therapeutic limits in renal cancer.
Lancet. 2011;378(9807):1898–900.
13. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, B.J. Eigl, J.D.
Ruether, T. Cheng, S. North, P. Venner, J.J. Knox, K.N. Chi, C. Kollmannsberger, D.
F. McDermott, W.K. Oh, M.B. Atkins, R.M. Bukowski, B.I. Rini, and T.K. Choueiri.
Prognostic factors for overall survival in patients with metastatic renal cell
carcinoma treated with vascular endothelial growth factor-targeted agents:
results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.
14. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential
therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer.
2009;115(1):61–7.
15. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier J.
Medioni and B. Escudier. Sequential sorafenib and sunitinib for renal cell
carcinoma. J Urol. 2009;182(1):29–34. discussion 34.
16. Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J.
2008;14(5):325–9.
17. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, B.I. Rini, and R.
M. Bukowski. Antitumor effects of sunitinib or sorafenib in patients with
metastatic renal cell carcinoma who received prior antiangiogenic therapy.
J Urol. 2008;179(1):81–6. discussion 86.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chittoria et al. BMC Cancer  (2016) 16:254 Page 7 of 7
